{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:08:45Z","timestamp":1777450125531,"version":"3.51.4"},"reference-count":101,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMAHP"],"abstract":"<jats:p>Health Technology Assessment (HTA) frameworks increasingly recognize the broader value elements of vaccines; however, their adoption remains inconsistent across jurisdictions and often incomplete in practice. Many HTA processes continue to prioritize narrow clinical outcomes and direct costs, leading to the underrepresentation of the full preventive and long-term benefits of vaccination. Building on the ISPOR \u201cElements of Value\u201d framework and recent evidence, this study adapts and expands existing models specifically for vaccines to enhance HTA applicability in both high-income and resource-limited settings. We introduce an updated vaccine value framework comprising 21 distinct value elements. Notably, the original model was expanded by introducing four entirely new value drivers: (1) real-world evidence; (2) control of antimicrobial resistance; (3) health system strengthening; and (4) environmental impact. Additionally, existing elements were refined, such as broadening \u201cfear of contagion\u201d to \u201cpeace of mind\u201d and expanding \u201cproductivity\u201d to capture education and leisure gains. We map these elements to potential data sources and methodological tools to facilitate their inclusion in HTA. This study offers an operational, holistic, and context-sensitive framework that reflects current advancements in assessment. By capturing the full spectrum of vaccine value, this framework aims to support more comprehensive, transparent, and equitable HTA decision-making for global immunization programs, while considering conceptual overlap between value elements to reduce the risk of double counting.<\/jats:p>","DOI":"10.3390\/jmahp14020024","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:33:37Z","timestamp":1777376017000},"page":"24","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Introducing an Expanded Value Framework in Health Technology Assessment of Vaccines"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7575-8816","authenticated-orcid":false,"given":"Farzaneh","family":"Eslami","sequence":"first","affiliation":[{"name":"Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6932-3930","authenticated-orcid":false,"given":"Thi Hao","family":"Pham","sequence":"additional","affiliation":[{"name":"Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angga P.","family":"Kautsar","sequence":"additional","affiliation":[{"name":"Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands"},{"name":"Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia"},{"name":"Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung 45363, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-9330","authenticated-orcid":false,"given":"Cao Ba","family":"Khuong","sequence":"additional","affiliation":[{"name":"Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands"},{"name":"Faculty of Public Health, Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen 250000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[{"name":"Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands"},{"name":"Health-Ecore, 3704 HE Zeist, The Netherlands"},{"name":"Health-Ecore, 9728 JT Groningen, The Netherlands"},{"name":"Department of Management Sciences, Open University, 6419 AT Heerlen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[{"name":"Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France"},{"name":"InovIntell, 30-605 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-1191","authenticated-orcid":false,"given":"Jurjen","family":"van der Schans","sequence":"additional","affiliation":[{"name":"Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands"},{"name":"Health-Ecore, 3704 HE Zeist, The Netherlands"},{"name":"Health-Ecore, 9728 JT Groningen, The Netherlands"},{"name":"Department of Management Sciences, Open University, 6419 AT Heerlen, The Netherlands"},{"name":"Department of Economics, Econometrics and Finance, Faculty of Economics & Business, University of Groningen, 9747 AJ Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[{"name":"Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands"},{"name":"Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung 45363, Indonesia"},{"name":"Health-Ecore, 3704 HE Zeist, The Netherlands"},{"name":"Health-Ecore, 9728 JT Groningen, The Netherlands"},{"name":"Department of Economics, Econometrics and Finance, Faculty of Economics & Business, University of Groningen, 9747 AJ Groningen, The Netherlands"},{"name":"Division of Pharmacology & Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya 60115, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10198-017-0871-0","article-title":"Using health technology assessment to assess the value of new medicines: Results of a systematic review and expert consultation across eight European countries","volume":"19","author":"Angelis","year":"2018","journal-title":"Eur. J. Health Econ."},{"key":"ref_2","unstructured":"Vogler, S., Haasis, M.A., Dedet, G., Lam, J., and Bak Pedersen, H. (2018). Medicines Reimbursement Policies in Europe, WHO."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1377\/hlthaff.10.3.22","article-title":"Health care systems in twenty-four countries","volume":"10","author":"Schieber","year":"1991","journal-title":"Health Aff."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40258-021-00683-z","article-title":"Towards a broader assessment of value in vaccines: The BRAVE way forward","volume":"20","author":"Bell","year":"2022","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_5","unstructured":"Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., and Torrance, G.W. (2015). Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press. [4th ed.]."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12911","DOI":"10.1073\/pnas.1717161115","article-title":"Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR","volume":"115","author":"Sevilla","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1016\/j.vaccine.2022.04.050","article-title":"Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework","volume":"40","author":"Beck","year":"2022","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"A676","DOI":"10.1016\/j.jval.2014.08.2515","article-title":"Cost-Effectiveness of Human Papillomavirus Vaccination Programmes Parallel to Current Routine Vaccination of Young Teenage Girls","volume":"17","author":"Westra","year":"2014","journal-title":"Value Health"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Buck, P.O., Gomes, D.A., Beck, E., Kirson, N., Mattera, M., Carroll, S., Ultsch, B., Jayasundara, K., Uhart, M., and Garrison, J. (2024). New Vaccine Platforms\u2014Novel Dimensions of Economic and Societal Value and Their Measurement. Vaccines, 12.","DOI":"10.3390\/vaccines12030234"},{"key":"ref_10","first-page":"453","article-title":"Le implicazioni economiche delle vaccinazioni: Una revisione sistematica delle valutazioni economiche e di HTA condotte in Italia [The economic value of vaccinations: A systematic review of Italian economic evaluations and HTA reports]","volume":"74","author":"Boccalini","year":"2017","journal-title":"Ig. Sanit\u00e0 Pubblica"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Di Fusco, M., Mendes, D., Steuten, L., Bloom, D.E., Drummond, M., Hauck, K., Pearson-Stuttard, J., Power, R., Salisbury, D., and Towse, A. (2023). The societal value of vaccines: Expert-based conceptual framework and methods using COVID-19 vaccines as A case study. Vaccines, 11.","DOI":"10.3390\/vaccines11020234"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1016\/j.vaccine.2022.04.026","article-title":"Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts","volume":"40","author":"Postma","year":"2022","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100096","DOI":"10.1016\/j.jvacx.2021.100096","article-title":"Realising the broader value of vaccines in the UK","volume":"8","author":"Brassel","year":"2021","journal-title":"Vaccine X"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.2147\/RMHP.S310215","article-title":"Health technology assessment in high, middle, and low-income countries: New systematic and interdisciplinary approach for sound informed-policy making: Research protocole","volume":"14","author":"Alkhaldi","year":"2021","journal-title":"Risk Manag. Healthc. Policy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13690-021-00754-6","article-title":"Differences between health technology assessment topics in high-and middle-income countries: A scoping review","volume":"79","author":"Ghazinoory","year":"2021","journal-title":"Arch. Public Health"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mbau, R., Vassall, A., Gilson, L., and Barasa, E. (2023). Factors influencing institutionalization of health technology assessment in Kenya. BMC Health Serv. Res., 23.","DOI":"10.1186\/s12913-023-09673-4"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ramponi, F., Twea, P., Chilima, B., Nkhoma, D., Kazanga Chiumia, I., Manthalu, G., Mfutso-Bengo, J., Revill, P., Drummond, M., and Sculpher, M. (2022). Assessing the potential of HTA to inform resource allocation decisions in low-income settings: The case of Malawi. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.1010702"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jval.2018.08.005","article-title":"Economic analysis of vaccination programs: An ISPOR good practices for outcomes research task force report","volume":"21","author":"Mauskopf","year":"2018","journal-title":"Value Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014A health economics approach: An ISPOR Special Task Force report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/amajethics.2021.639","article-title":"How does cost-effectiveness analysis inform health care decisions?","volume":"23","author":"Kim","year":"2021","journal-title":"AMA J. Ethics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13690-021-00729-7","article-title":"The application of the QALY measure in the assessment of the effects of health interventions on an older population: A systematic scoping review","volume":"79","author":"Kocot","year":"2021","journal-title":"Arch. Public Health"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Beekman, J., de Roo, A., Wolters, S., Marapin, R., Gurgel do Amaral, G., Dvortsin, E., Quilici, S., de Waure, C., Petelos, E., and Postma, M. (2025). Strengthening the EU Health Technology Assessment Regulation: Integrating National Immunization Technical Advisory Groups for Comprehensive Vaccine Assessments. J. Mark. Access Health Policy, 13.","DOI":"10.3390\/jmahp13020016"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wilder-Smith, A., Longini, I., Zuber, P., B\u00e4rnighausen, T., Edmunds, W., Dean, N., Spicher, V.M., Benissa, M., and Gessner, B. (2017). The public health value of vaccines beyond efficacy: Methods, measures and outcomes. BMC Med., 15.","DOI":"10.1186\/s12916-017-0911-8"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jval.2020.09.018","article-title":"Preferences for e-mental health interventions in Germany: A discrete choice experiment","volume":"24","author":"Phillips","year":"2021","journal-title":"Value Health"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2060017","DOI":"10.1080\/21645515.2022.2060017","article-title":"Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review","volume":"18","author":"Bencina","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1017\/S0266462320000124","article-title":"Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?","volume":"36","author":"Feng","year":"2020","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S323292","article-title":"Unraveling COVID-19: A large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS","volume":"14","author":"Kostka","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Burns, L., Le Roux, N., Kalesnik-Orszulak, R., Christian, J., Dudinak, J., Rockhold, F., Khozin, S., and O\u2019Donnell, J. (2023). Real-world evidence for regulatory decision-making: Updated guidance from around the world. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1236462"},{"key":"ref_29","unstructured":"Makady, A.A.M.A. (2018). Real-World Evidence for Health Technology Assessment of Pharmaceuticals: Opportunities and Challenges. [Ph.D. Thesis, Utrecht University]."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.3389\/jpps.2023.11460","article-title":"Integration of real-world evidence from different data sources in health technology assessment","volume":"26","author":"Graili","year":"2023","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101750","DOI":"10.1016\/j.biologicals.2024.101750","article-title":"The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment\u2014A meeting report","volume":"85","author":"Bollaerts","year":"2024","journal-title":"Biologicals"},{"key":"ref_32","unstructured":"Lin, L.W., Ahn, J., Bayani, D.B.S., Chan, K., Choiphel, D., Isaranuwatchai, W., Kc, S., Kearney, B., Lou, J., and Adler, A. (2023, March 03). Use of Real-World Data and Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia. Available online: https:\/\/hiper.nus.edu.sg\/realise-guidance\/."},{"key":"ref_33","first-page":"E150","article-title":"How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project","volume":"56","author":"Gasparini","year":"2015","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Holubar, M., Stavroulakis, M.C., Maldonado, Y., Ioannidis, J.P., and Contopoulos-Ioannidis, D. (2017). Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172414"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1093\/infdis\/jiac183","article-title":"Impact of respiratory syncytial virus on child, caregiver, and family quality of life in the United States: Systematic literature review and analysis","volume":"226","author":"Glaser","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1875762","article-title":"Patient-reported outcomes in vaccines research: Relevance for decision-making","volume":"18","author":"Curran","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Calabro\u2019, G.E., Carini, E., Tognetto, A., Giacchetta, I., Bonanno, E., Mariani, M., Ricciardi, W., and De Waure, C. (2022). The value(s) of vaccination: Building the scientific evidence according to a value-based healthcare approach. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.786662"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/ebmental-2021-300334","article-title":"Patient-reported outcome measures suitable for quality of life\/well-being assessment in multisectoral, multinational and multiperson mental health economic evaluations","volume":"25","author":"Helter","year":"2022","journal-title":"Evid. Based Ment. Health"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/j.jval.2022.09.1502","article-title":"HTA42 Use of Health-Related Quality of Life (HRQoL) Outcomes\/Patient-Reported Outcomes (PROs) in Rare Hematological Disease (RHD) Health Technology Assessment (HTA) Submissions","volume":"25","author":"Thakur","year":"2022","journal-title":"Value Health"},{"key":"ref_40","unstructured":"van Lier, E., and de Melker, H. (2019). Herpes Zoster in the Netherlands. Background Information for the Health Council, National Institute for Public Health and the Environment."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2013.12.029","article-title":"How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam\u2019s Expanded Program on Immunization","volume":"32","author":"Mvundura","year":"2014","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40273-021-01053-2","article-title":"The challenges of measuring informal care time: A review of the literature","volume":"39","author":"Urwin","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"23897","DOI":"10.3402\/jmahp.v2.23897","article-title":"Is the gap between micro-and macroeconomic assessments in health care well understood? The case of vaccination and potential remedies","volume":"2","author":"Kotsopoulos","year":"2014","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.103.6.e73","article-title":"Potential cost savings attributable to influenza vaccination of school-aged children","volume":"103","author":"White","year":"1999","journal-title":"Pediatrics"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hutubessy, R., Lauer, J.A., Giersing, B., Sim, S.Y., Jit, M., Kaslow, D., and Botwright, S. (2023). The Full Value of Vaccine Assessments (FVVA): A framework for assessing and communicating the value of vaccines for investment and introduction decision-making. BMC Med., 21.","DOI":"10.1186\/s12916-023-02929-0"},{"key":"ref_46","unstructured":"JCVI (2023, October 06). JCVI Statement on Vaccination of Children Aged 5 to 11 Years Old, Available online: https:\/\/www.gov.uk\/government\/publications\/jcvi-update-on-advice-for-covid-19-vaccination-of-children-aged-5-to-11\/jcvi-statement-on-vaccination-of-children-aged-5-to-11-years-old#references."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.jval.2018.04.1828","article-title":"Time is money: Investigating the value of leisure time and unpaid work","volume":"21","author":"Verbooy","year":"2018","journal-title":"Value Health"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40258-018-0416-4","article-title":"Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: A review","volume":"16","author":"Pike","year":"2018","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00000441-200103000-00004","article-title":"School absenteeism, parental work loss, and acceptance of childhood influenza vaccination","volume":"321","author":"Nettleman","year":"2001","journal-title":"Am. J. Med. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Badura, B., Ducki, A., Meyer, M., Baumgardt, J., and Schr\u00f6der, H. (2023). Fehlzeiten-Report 2023: Zeitenwende-Arbeit Gesund Gestalten, Springer.","DOI":"10.1007\/978-3-662-67514-4"},{"key":"ref_51","unstructured":"Zwaap, J., van der Meijden, C., McCabe, C., and Stolk, E. (2015). Cost-Effectiveness in Dutch Healthcare: A Report for the National Health Care Institute (Zorginstituut Nederland), Zorginstituut Nederland."},{"key":"ref_52","unstructured":"Gezondheidsraad (2018). Vaccinatie Tegen Meningokokken B, Gezondheidsraad. 2018\/19."},{"key":"ref_53","unstructured":"(2024). Vaccinatie Tegen Griep: Een Nieuw Programma, Gezondheidsraad. Nr. 2024\/18."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jval.2021.05.020","article-title":"Modeling the cost-utility of treatment sequences for multiple sclerosis","volume":"24","author":"Huygens","year":"2021","journal-title":"Value Health"},{"key":"ref_55","unstructured":"iMTA (2026, January 10). iMTA Burden of Disease Calculator. Available online: https:\/\/www.imta.nl\/tools\/idbc\/."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jiph.2016.09.006","article-title":"Vaccination adherence: Review and proposed model","volume":"9","author":"Abahussin","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13290","article-title":"Sensitivity analysis in economic evaluation: An audit of NICE current practice and a review of its use and value in decision-making","volume":"13","author":"Andronis","year":"2009","journal-title":"Health Technol. Assess."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.46234\/ccdcw2024.265","article-title":"Cost-Effectiveness Analysis of Vaccination Compliance Strategies Using a Novel Hybrid Model for Influenza Vaccination","volume":"6","author":"You","year":"2024","journal-title":"China CDC Wkly."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff. Resour. Alloc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1473-3099(16)00027-X","article-title":"Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: A historical analysis","volume":"16","author":"McDonald","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_61","unstructured":"Barnsley, P., Cubi-Molla, P., Fischer, A., and Towse, A. (2026, January 10). Uncertainty and Risk in HTA Decision Making. OHE Research Paper. Available online: https:\/\/www.ohe.org\/publications\/uncertainty-and-risk-hta-decision-making."},{"key":"ref_62","first-page":"400","article-title":"Augmenting cost-effectiveness analysis for uncertainty: The implications for value assessment\u2014Rationale and empirical support","volume":"26","author":"Garrison","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_64","first-page":"98","article-title":"Rising costs of COPD and the potential for maintenance therapy to slow the trend","volume":"7","author":"Blanchette","year":"2014","journal-title":"Am. Health Drug Benefits"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Johansson, K.A., Memirie, S.T., Pecenka, C., Jamison, D.T., and Verguet, S. (2015). Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: Results from an extended cost-effectiveness analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142691"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wondimu, A., van der Schans, J., van Hulst, M., and Postma, M.J. (2020). Inequalities in rotavirus vaccine uptake in Ethiopia: A decomposition analysis. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17082696"},{"key":"ref_67","first-page":"1185","article-title":"Reflections on the ISPOR special task force on US value frameworks: Implications of a health economics approach for managed care pharmacy","volume":"25","author":"Garrison","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_68","first-page":"883","article-title":"A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC)","volume":"32","author":"Kitchener","year":"2016","journal-title":"Health Technol. Assess."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","article-title":"Discrete choice experiments in health economics: A review of the literature","volume":"32","author":"Clark","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jval.2021.04.1284","article-title":"Quantifying value of hope","volume":"24","author":"Reed","year":"2021","journal-title":"Value Health"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jval.2022.03.006","article-title":"Should We Consider Including a Value for \u201cHope\u201d as an Additional Benefit Within Health Technology Assessment?","volume":"25","author":"Peasgood","year":"2022","journal-title":"Value Health"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.vaccine.2019.12.009","article-title":"Understanding the role of peace of mind in childhood vaccination: A qualitative study with members of the general public","volume":"38","author":"Lasseter","year":"2020","journal-title":"Vaccine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100651","DOI":"10.1016\/j.ssmph.2020.100651","article-title":"The impact of Covid-19, associated behaviours and policies on the UK economy: A computable general equilibrium model","volume":"12","author":"Jensen","year":"2020","journal-title":"SSM-Popul. Health"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Guirado-Fuentes, C., Abt-Sacks, A., Trujillo-Mart\u00edn, M.d.M., Garc\u00eda-P\u00e9rez, L., Rodr\u00edguez-Rodr\u00edguez, L., Carrion i Ribas, C., and Serrano-Aguilar, P. (2023). Main challenges of incorporating environmental impacts in the economic evaluation of health technology assessment: A scoping review. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20064949"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.estlett.2c00446","article-title":"GREENER pharmaceuticals for more sustainable healthcare","volume":"9","author":"Moermond","year":"2022","journal-title":"Environ. Sci. Technol. Lett."},{"key":"ref_76","unstructured":"UK Health Security Agency, NHS England, and Department of Health and Social Care (2026, January 10). National Flu Immunisation Programme 2023 to 2024 Letter, Available online: https:\/\/www.gov.uk\/government\/publications\/national-flu-immunisation-programme-plan\/national-flu-immunisation-programme-2023-to-2024-letter."},{"key":"ref_77","unstructured":"Hulst, J.G. (2022). Measuring and Improving the Impact of Sustainable Public Procurement of Immunization Cold Chain Equipment by UNICEF, University of Twente."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14760584.2024.2387599","article-title":"The broader benefits of vaccines: Methodologies for inclusion in economic evaluation","volume":"23","author":"Simoens","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jval.2024.04.022","article-title":"Documenting the Full Value of Vaccination: A Systematic Review of Value Frameworks","volume":"27","author":"Riley","year":"2024","journal-title":"Value Health"},{"key":"ref_80","first-page":"16","article-title":"Quantifying the benefits of vaccines in combating antimicrobial resistance","volume":"26","author":"Jit","year":"2020","journal-title":"Eurohealth"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bcp.14651","article-title":"Overuse of antibiotics: Can viral vaccinations help stem the tide?","volume":"87","author":"Miller","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_82","unstructured":"Olsen, L., Saunders, R.S., and Yong, P.L. (2011). The Healthcare Imperative: Lowering Costs and Improving Outcomes: Workshop Series Summary, National Academies Press."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/20479700.2024.2312630","article-title":"The impact of hospital surge capacity during the 2009 influenza pandemic on patient safety: A systematic review","volume":"18","author":"Dhamanti","year":"2024","journal-title":"Int. J. Healthc. Manag."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jval.2022.11.020","article-title":"Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: The case of switching to High-Dose influenza vaccine for Dutch older adults","volume":"26","author":"Zeevat","year":"2023","journal-title":"Value Health"},{"key":"ref_85","first-page":"24","article-title":"The ABCs of Real Option Value of Medical Technologies","volume":"1","author":"Li","year":"2020","journal-title":"Value Outcomes Spotlight"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jval.2019.02.002","article-title":"How does option value affect the potential cost-effectiveness of a treatment? The case of ipilimumab for metastatic melanoma","volume":"22","author":"Li","year":"2019","journal-title":"Value Health"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40273-024-01396-6","article-title":"The value of flexible vaccine manufacturing capacity: Value drivers, estimation methods, and approaches to value recognition in health technology assessment","volume":"42","author":"McElwee","year":"2024","journal-title":"PharmacoEconomics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jval.2020.12.018","article-title":"Broadening the concept of value: A scoping review on the option value of medical technologies","volume":"24","author":"Fornaro","year":"2021","journal-title":"Value Health"},{"key":"ref_89","unstructured":"WHO (2025, October 06). Social Determinants of Health. Available online: https:\/\/www.who.int\/health-topics\/social-determinants-of-health#tab=tab_1."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Patikorn, C., Cho, J.-Y., Lambach, P., Hutubessy, R., and Chaiyakunapruk, N. (2023). Equity-Informative Economic Evaluations of Vaccines: A Systematic Literature Review. Vaccines, 11.","DOI":"10.3390\/vaccines11030622"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40273-021-01094-7","article-title":"Incorporating equity concerns in cost-effectiveness analyses: A systematic literature review","volume":"40","author":"Ward","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Daems, R., and Maes, E. (2022). The race for COVID-19 vaccines: Accelerating innovation, fair allocation and distribution. Vaccines, 10.","DOI":"10.3390\/vaccines10091450"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.omtm.2023.08.002","article-title":"Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec","volume":"30","author":"Asher","year":"2023","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_94","unstructured":"Rej\u00f3n Parrilla, J.C. (2024). The Value and Measurement of Innovation in Health Technology Assessment and Its Impact on Public Financing of Medicines. [Ph.D. Thesis, Universidad de Granada]."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"A29","DOI":"10.1016\/j.vaccine.2016.12.001","article-title":"Moving beyond traditional valuation of vaccination: Needs and opportunities","volume":"35","author":"Bloom","year":"2017","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jval.2019.06.014","article-title":"Multicriteria decision analysis to support health technology assessment agencies: Benefits, limitations, and the way forward","volume":"22","author":"Baltussen","year":"2019","journal-title":"Value Health"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1017\/S0266462322000265","article-title":"Health technology assessment in support of national health insurance in South Africa","volume":"38","author":"Wilkinson","year":"2022","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"White, R.G., Menzies, N.A., Portnoy, A., Clark, R.A., Toscano, C.M., Weller, C., Tufet Bayona, M., Silal, S.P., Karron, R.A., and Lee, J.-S. (2024). The Full Value of Vaccine Assessments Concept\u2014Current Opportunities and Recommendations. Vaccines, 12.","DOI":"10.3390\/vaccines12040435"},{"key":"ref_99","unstructured":"Michaels, J. (Journal of Medical Ethics Blog, 2021). Valuing the care in healthcare: Priorities and trade-offs, Journal of Medical Ethics Blog."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1017\/S0266462324000230","article-title":"Health technology assessment and healthcare environmental sustainability: Prioritizing effort and maximizing impact","volume":"40","author":"Hensher","year":"2024","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00002018-199615050-00002","article-title":"Acellular pertussis vaccines: Towards an improved safety profile","volume":"15","author":"Pichichero","year":"1996","journal-title":"Drug Saf."}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/2\/24\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:42:36Z","timestamp":1777380156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/2\/24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":101,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jmahp14020024"],"URL":"https:\/\/doi.org\/10.3390\/jmahp14020024","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}